India's generic semaglutide rush slashes weight-loss drug costs by half

Generic versions of semaglutide-based weight-loss injections have hit the Indian market at roughly half the previous cost. The move follows last week's expiry of patent protections for semaglutide—the key ingredient in drugs like Ozempic and Wegovy—in several major countries. India, a leading producer of affordable medications, is now seeing fierce competition among local manufacturers. At least three Indian pharmaceutical firms have already launched their own semaglutide products. Eris Lifesciences released Sundae, while Alkem Laboratories introduced Semasize, Obesema, and Hepaglide on March 21, 2026. Glenmark Pharmaceuticals also entered the market with Glipiq. Industry experts predict up to 50 such brands could emerge soon, now that patent restrictions have lifted.

Prices for these generic injections in India now range between 15 and 35 Swiss francs per month. As more companies join the market, costs are expected to drop even further. The lower prices come as obesity rates in India climb, with projections suggesting around 450 million severely obese individuals by 2050. India's pharmaceutical sector, however, operates with loose regulations. Many prescription-only medications, including these injections, can be bought without a doctor's approval. The country's beauty standards—heavily influenced by Bollywood and health trends—also drive demand for weight-loss treatments. Swiss residents can legally bring a one-month supply of these generics into Switzerland for personal use. Yet Swissmedic, the national drug regulator, has issued warnings about ordering such products from abroad. The agency highlights risks of counterfeit or poor-quality medications entering the market.

The arrival of cheap generic semaglutide in India marks a major shift in the weight-loss drug market. With prices set to fall further, access to these treatments will likely expand. However, concerns remain over India's weak regulatory oversight and the potential dangers of unchecked imports into countries like Switzerland.